Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease

Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease

Abstract Brain-derived neurotrophic factor (BDNF) is implicated in the survival of striatal neurons. BDNF function is reduced in Huntington’s disease (HD), possibly because mutant huntingtin impairs its cortico-striatal transport, contributing to striatal neurodegeneration. The BDNF trophic pathway...

Full description

Bibliographic Details
Main Authors:	Zhen-Yi Andy Ou, Lauren M. Byrne, Filipe B. Rodrigues, Rosanna Tortelli, Eileanoir B. Johnson, Martha S. Foiani, Marzena Arridge, Enrico De Vita, Rachael I. Scahill, Amanda Heslegrave, Henrik Zetterberg, Edward J. Wild
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-02-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-83000-x

Similar Items

Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.
by: Alexander J Lowe, et al.
Published: (2020-01-01)

Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease.
by: Filipe Brogueira Rodrigues, et al.
Published: (2016-01-01)

Brain-derived neurotrophic factor in patients with Huntington's disease.
by: Chiara Zuccato, et al.
Published: (2011-01-01)

The Cerebrospinal Fluid in Multiple Sclerosis
by: Florian Deisenhammer, et al.
Published: (2019-04-01)

Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease.
by: Valter Niemelä, et al.
Published: (2018-01-01)

Structural cortical grey matter changes during the transition from premanifest to manifest Huntington's disease : a methodological evaluation
by: Johnson, Eileanoir
Published: (2018)

Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington’s Disease
by: Nina M. Mansoor, et al.
Published: (2021-04-01)

Interlaboratory validation of cerebrospinal fluid α‐synuclein quantification in the diagnosis of sporadic Creutzfeldt‐Jakob disease
by: Niels Kruse, et al.
Published: (2018-01-01)

A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntington’s Disease
by: Peter A. Wijeratne, et al.
Published: (2021-08-01)

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington’s Disease
by: Eileanoir B. Johnson, et al.
Published: (2017-10-01)

Neuromodulation via the Cerebrospinal Fluid: Insights from Recent in Vitro Studies
by: Andreas Bjorefeldt, et al.
Published: (2018-02-01)

A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
by: Xiaofang Zhong, et al.
Published: (2019-01-01)

Plasma Markers of Neurodegeneration Are Raised in Friedreich’s Ataxia
by: Anna M. Zeitlberger, et al.
Published: (2018-10-01)

Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington’s disease
by: Shotaro Kishikawa, et al.
Published: (2006-11-01)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
by: Henrik Zetterberg, et al.
Published: (2010-01-01)

Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup
by: Ione O. C. Woollacott, et al.
Published: (2018-08-01)

Quantitative Analysis of Cerebrospinal Fluid Brain Derived Neurotrophic Factor in the Patients with Multiple Sclerosis
by: Farhad Mashayekhi, et al.
Published: (2012-01-01)

Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
by: Anna M. De Kort, et al.
Published: (2021-09-01)

Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease.
by: Yen-Chu Huang, et al.
Published: (2011-01-01)

Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
by: Carmela Giampà, et al.
Published: (2013-01-01)

Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects.
by: Ge Li, et al.
Published: (2009-01-01)

Identification and evaluation of biomarkers for Huntington's disease
by: Wild, E. J.
Published: (2009)

Correction: Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington's Disease.
by: Carmela Giampà, et al.
Published: (2016-01-01)

Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study
by: Eileanoir B. Johnson, et al.
Published: (2021-03-01)

Psychological distress in the context of Huntington's disease
by: Theed, Rachael
Published: (2016)

Peptidome analysis of cerebrospinal fluid by LC-MALDI MS.
by: Mikko Hölttä, et al.
Published: (2012-01-01)

Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington’s Disease Patients
by: Ashley Gutierrez, et al.
Published: (2020-01-01)

Huntington's Disease: The Most Curable Incurable Brain Disorder?
by: Edward J. Wild
Published: (2016-06-01)

Localised phosphorus spectroscopy 'in vivo' : quantitation of metabolite concentrations
by: Wylezinska-Arridge, Marzena Malgorzata
Published: (1997)

Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays.
by: Davina J Hensman Moss, et al.
Published: (2017-01-01)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
by: Lovisa Tobieson, et al.
Published: (2021-08-01)

Altered Intracortical T1-Weighted/T2-Weighted Ratio Signal in Huntington’s Disease
by: Christopher D. Rowley, et al.
Published: (2018-11-01)

Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
by: Elizabeta B. Mukaetova-Ladinska, et al.
Published: (2010-01-01)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
by: Maria Bjerke, et al.
Published: (2010-01-01)

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease
by: Raquel Sánchez-Valle, et al.
Published: (2018-11-01)

Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study
by: Bromander Sara, et al.
Published: (2012-10-01)

Evidence of a Muscle–Brain Axis by Quantification of the Neurotrophic Myokine METRNL (Meteorin-Like Protein) in Human Cerebrospinal Fluid and Serum
by: Martin Berghoff, et al.
Published: (2021-07-01)

Stability of blood‐based biomarkers of Alzheimer's disease over multiple freeze‐thaw cycles
by: Ashvini Keshavan, et al.
Published: (2018-01-01)

KONFLIK PERADABAN SAMUEL P. HUNTINGTON (Kebangkitan Islam yang Dirisaukan?)
by: Vita Fitria
Published: (2009-09-01)

Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic
by: Ross W. Paterson, et al.
Published: (2018-03-01)

Cannot write session to /tmp/vufind_sessions/sess_i3a2qebbka4fhurjpb2kr29flv